Ritter Pharmaceuticals (NASDAQ:RTTR) received three new patents for the development of its company RP-G28.
As quoted in the press release:
The Company is also providing an update on its phase 3 program based on conversations with regulatory authorities and experts.
The Company has been issued two new U.S. patents and one new Australian patent. The two new U.S. patents (U.S. Patent Nos. 9,579,340 and 9,592,248) are directed to compositions containing RP-G28 and methods of using RP-G28, further strengthening the intellectual property positions of RP-G28. The issuance of an Australian patent (No. 20102184) provides additional international protection for compositions containing the compound.
“We are pleased to add these additional issued patents to our portfolio of issued and pending claims, providing both validation and protection for our compound, RP-G28, in development for the treatment of lactose intolerance,” stated Michael Step, CEO of Ritter Pharmaceuticals. “We now have 15 issued patents and over 25 additional pending patent applications. This additional intellectual property continues to protect our compound and its uses, likely beyond 2030.”